USFDA concludes routine cGMP inspection at Cipla’s manufacturing facility in Patalganga

05 Apr 2024 Evaluate

United States Food and Drug Administration (USFDA) has concluded routine current Good Manufacturing Practices (cGMP) inspection at Cipla’s manufacturing facility located in Patalganga, Maharashtra, India from March 28, 2024 to April 4, 2024.

On conclusion of the inspection, the company has received 6 inspectional observations in Form 483. The company will work closely with the USFDA and is committed to address these comprehensively within the stipulated time. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. 


Cipla Share Price

1554.40 28.90 (1.89%)
28-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1841.80
Dr. Reddys Lab 1199.70
Cipla 1554.40
Lupin 2107.70
Zydus Lifesciences 885.85
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...